CRL

AI Memo

Charles River Laboratories International

As of 2026-06-23/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-06-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Divestiture close could lift margin mix and simplify the story • 2026-06-30

Expected move: +6%

Biggest risk

Bear case is that the operating improvement remains more stabilization than growth: Q1 organic revenue still declined 1.5%, non-GAAP operating margin fell to 16.3% from 19.1%, and the key drivers of pressure were higher DSA study costs, unfavorable RMS mix, and executive-transition compensation [#SEC-8K-2026-05-07]. If biotech/customer demand stays mixed, a cleaner portfolio may not be enough to restore stronger growth quickly.

Invalidation

Break below $160 or thesis failure.

What would change my mind?

Bull case is a cautious recovery/setup: Q1 met management’s internal targets, guidance was reaffirmed, DSA bookings were described as solid, and the portfolio is being simplified through divestitures that management said should improve 2026 margin and EPS mix [#SEC-8K-2026-05-07] [#IR-2026-02-25]. The June 18 Lilly TuneLab collaboration also supports a more modernized, higher-value client engagement narrative [#IR-2026-06-18].

Research note

Recommendation

—

Confidence

medium

As of

2026-06-23

Base target

$198

p=50%

Bull target

$215

p=30%

Bear target

$160

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 results kept full-year outlook intact despite softer organic growth
Lilly TuneLab collaboration adds an AI-enabled client-acquisition angle
Bull case is a cautious recovery/setup: Q1 met management’s internal targets, guidance was reaffirmed, DSA bookings were described as solid, and the portfolio is being simplified through divestitures that management said should improve 2026 margin and EPS mix [#SEC-8K-2026-05-07] [#IR-2026-02-25].

BearKey bullets

Non-GAAP operating margin compressed to 16.3% from 19.1% because of higher DSA study-related direct costs, unfavorable RMS revenue mix, and higher stock-based compensation tied largely to executive transition [#SEC-8K-2026-05-07].
Organic revenue was down 1.5% in Q1 2026, so the core debate is still about demand recovery and mix, not just financial engineering [#SEC-8K-2026-05-07].
The Lilly TuneLab collaboration is strategically interesting but still early, so investors should not assume near-term material revenue contribution from the announcement alone [#IR-2026-06-18].

WatchKey bullets

Divestiture close could lift margin mix and simplify the story

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $198 (p=50%)

Bull/Bear spread: +15% / -14%

Vs latest close: Bull +15% · Base +6% · Bear -14%

Scenario probabilities

Bull Target: $215 (p=30%)Base Target: $198 (p=50%)Bear Target: $160 (p=20%)

Commentary

Near-term headline tone is modestly positive: the June 18 Lilly TuneLab announcement and June 17 sell-side upgrade/reporting around a $220 target helped the narrative, while the May 7 earnings release showed guidance stability rather than a full fundamental inflection. Coverage is not deep in the packet, social context is unavailable, and the stock at $181.56 on June 22, 2026 still sits below both the median target and its January high, so this remains a constructive monitoring view rather than a high-conviction rerating call.

As of 2026-06-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 results kept full-year outlook intact despite softer organic growth
Lilly TuneLab collaboration adds an AI-enabled client-acquisition angle

Scenarios

Bull Target (Scenario probability)

$215 / p=30% prob

Base Target (Scenario probability)

$198 / p=50% prob

Bear Target (Scenario probability)

$160 / p=20% prob

Price $187 as of 2026-06-23

Nearest Scenario: Base (∆ 6%)

Targets vs latest close: Bull +15% · Base +6% · Bear -14%

Sentiment & Exposure

News Sentiment (30d)

0.28

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-30
Divestiture close could lift margin mix and simplify the story
On February 25, 2026, Charles River said the planned CDMO/Cell Solutions and certain European Discovery divestitures were expected to close during Q2 2026, reduce 2026 revenue by slightly more than $200 million, but add at least 100 basis points of incremental non-GAAP operating margin improvement and about $0.10 of partial-year non-GAAP EPS accretion [#IR-2026-02-25].
Prob 65.00% • Move 9.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

Q1 results kept full-year outlook intact despite softer organic growth
2026-08-05
Charles River reported Q1 2026 revenue of $995.8 million, organic revenue down 1.5%, non-GAAP EPS of $2.06, and reaffirmed 2026 organic revenue and non-GAAP EPS guidance; management also said DSA demand was tracking to expectations with solid bookings, which supports a near-term stabilization thesis but not a clean reacceleration yet [#SEC-8K-2026-05-07].
Prob 70% • Move 7% • Priced-in 55%

Long-term Catalysts

Months to a year

Lilly TuneLab collaboration adds an AI-enabled client-acquisition angle
2026-12-31
On June 18, 2026, Charles River announced a collaboration with Lilly TuneLab under which Charles River will provide nonclinical testing services to participating companies; management framed the deal as part of a strategy to deepen client relationships and modernize R&D workflows, but the revenue timing is still early-stage [#IR-2026-06-18].
Prob 50% • Move 6% • Priced-in 30%

Risks

Non-GAAP operating margin compressed to 16.3% from 19.1% because of higher DSA study-related direct costs, unfavorable RMS revenue mix, and higher stock-based compensation tied largely to executive transition [#SEC-8K-2026-05-07].
Organic revenue was down 1.5% in Q1 2026, so the core debate is still about demand recovery and mix, not just financial engineering [#SEC-8K-2026-05-07].
The Lilly TuneLab collaboration is strategically interesting but still early, so investors should not assume near-term material revenue contribution from the announcement alone [#IR-2026-06-18].
The divestiture program lowers revenue scale in 2026 and depends on clean execution, while some consideration is contingent and transition costs are not fully finalized [#IR-2026-02-25].

Peers

Symbol	Summary
IQV	Most relevant operating peer/read-through. IQVIA agreed on February 25, 2026 to buy Charles River discovery assets, highlighting overlap in outsourced drug-discovery services and implying strategic value for Charles River’s retained portfolio even after pruning non-core assets.
MEDP	Broader CRO comp rather than a perfect preclinical match. Medpace’s full-service CRO/lab model is a useful sentiment benchmark for outsourced drug-development demand, but its heavier clinical exposure makes it an imperfect valuation comp for CRL’s preclinical and research-model mix.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-06-23

Loading AI feed…

Symbol

Summary

IQV

Most relevant operating peer/read-through. IQVIA agreed on February 25, 2026 to buy Charles River discovery assets, highlighting overlap in outsourced drug-discovery services and implying strategic value for Charles River’s retained portfolio even after pruning non-core assets.

MEDP

Broader CRO comp rather than a perfect preclinical match. Medpace’s full-service CRO/lab model is a useful sentiment benchmark for outsourced drug-development demand, but its heavier clinical exposure makes it an imperfect valuation comp for CRL’s preclinical and research-model mix.